ESR1 and breast cancer: H3B-5942 was the first-in-class experimental oral compound with high selectivity for C530 demonstrating superior antitumor activity to fulvestrant in preclinical BC xenograft models with both ESR1 Y37S mutation and ESR1 wild type.